Abstract 309P
Background
Extensive-stage small-cell lung cancer (ES-SCLC) is associated with a poor prognosis. CASPIAN demonstrated that the combination of durvalumab and platinum-etoposide as a first-line treatment for patients with ES-SCLC significantly prolonged overall survival. CANTABRICO was a single-arm clinical trial focused on evaluating the safety and effectiveness of durvalumab plus platinum-etoposide as first-line treatment in a real-world population of patients with ES-SCLC in Spain. Herein, we present the results of patients who achieved a long-term benefit in CANTABRICO trial.
Methods
In this exploratory analysis, long-term benefit (LTB) patients were defined as those who lived for at least 24 months after inclusion. Patients who were censored before 24 months were excluded from the analysis. Bivariate analysis was performed and considered significant if p < 0.05 (χ2 or Fisher).
Results
Overall, 101 patients were included in the study and received at least one dose of durvalumab, 98 of which were included in this analysis. Twenty-four patients (24.5%) were categorized as LTB. The median follow-up was 9.5 months (27.2 and 7.2 months for LTB and non-LTB [n=74], respectively). In the bivariate analysis, a better ECOG-PS was a factor associated with LTB (p < 0.05). A lower frequency of liver metastases and high tumor burden were highlighted factors associated with LTB. Objective response rates were 83.3% (LTB) and 44.6% (non-LTB). The frequency of grade 3–4 treatment-related AEs was comparable between LTB and non-LTB patients (55.1% vs. 55.4%), whereas no clinically meaningful differences were observed in the frequency of grade 3–4 immune-mediated AEs (12.5% vs 9.5%). However, patients with LTB showed a higher frequency of treatment-related AEs leading to discontinuation (25.0% vs 8.1%).
Conclusions
First-line treatment of patients with ES-SCLC with an initial regimen of up to 6 cycles of durvalumab plus platinum-etoposide followed by maintenance durvalumab is associated with a long-term benefit in a substantial proportion of patients without compromising safety profile. Better ECOG was statistically significant associated with LTB.
Clinical trial identification
EudraCT 2020-002328-35, NCT04712903.
Editorial acknowledgement
The authors and the sponsor would like to thank APICES for their editorial assistance.
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
M.D. Isla Casado: Financial Interests, Personal, Advisory Board: AstraZeneca, Roche, Johnson & Johnson, MSD, Amgen, Pfizer, Sanofi, BMS, GSK; Financial Interests, Personal, Invited Speaker: Pfizer, Roche, Johnson & Johnson, MSD, Lilly, Sanofi, Novartis, BMS, AstraZeneca, Merck. E. Arriola Aperribay: Financial Interests, Institutional, Research Grant: AstraZeneca, BMS; Financial Interests, Personal, Speaker’s Bureau: Lilly, AstraZeneca, Roche, Takeda, MSD, Pfizer, Janssen, BMS; Financial Interests, Personal, Other, Support for attending meetings and/or travel: AstraZeneca, Roche, Pfizer; Financial Interests, Institutional, Other, Receipt of equipment, materials, drugs, medical writing or other services: AstraZeneca. M.R. Garcia Campelo: Financial Interests, Personal, Other, Honoraria: Bristol Myers Squibb, MSD Oncology, AstraZeneca, Roche/Genentech, Takeda; Financial Interests, Personal, Advisory Role: GSK; Financial Interests, Personal, Other, Travel, Accommodations, Expense: Roche, AstraZeneca, Pfizer. C. Marti Blanco: Financial Interests, Personal, Invited Speaker: AstraZeneca, Bristol Myers Squibb, Pfizer; Non-Financial Interests, Institutional, Principal Investigator: AstraZeneca, Roche. P. Diz Tain: Financial Interests, Personal and Institutional, Invited Speaker: Bristol Myers Squib, AstraZeneca, Roche; Financial Interests, Personal and Institutional, Advisory Role: Bristol Myers Squib, AstraZeneca, Roche; Financial Interests, Personal and Institutional, Training: Bristol Myers Squib, AstraZeneca, Roche; Financial Interests, Personal and Institutional, Principal Investigator: Bristol Myers Squib, AstraZeneca, Roche; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim, MSD, Takeda, Pfizer, Amgen; Financial Interests, Personal, Advisory Role: Boehringer Ingelheim, MSD, Takeda; Financial Interests, Personal, Training: Boehringer Ingelheim, MSD, Takeda, Pfizer. L.A. Leon Mateos: Financial Interests, Personal, Expert Testimony: AstraZeneca, Bristol Myers Squibb, Merck, MSD, Roche, Sanofi, Takeda; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Bristol Myers Squibb, Jansen, Merck, MSD, Novartis, Pfizer, Roche, Sanofi, Takeda; Financial Interests, Personal, Other, Support for attending meetings and/or travel: AstraZeneca, Bristol Myers Squibb, Jansen, MSD, Pfizer, Roche, Sanofi, Takeda. M. Majem: Financial Interests, Personal, Advisory Board: Amgen, Roche, AstraZeneca, Takeda, Janssen, Casen Recordati, BMS, Sanofi, Pfizer; Financial Interests, Personal, Invited Speaker: Amgen, ROCHE, AstraZeneca, Pfizer, Takeda, Helsinn, Casen Recordati; Financial Interests, Institutional, Funding: BMS, AstraZeneca, Roche; Non-Financial Interests, Personal, Leadership Role, Board Member: Associacio Contra el cancer Barcelona; Non-Financial Interests, Personal, Leadership Role: Asocacion para la Investigacion del Cancer de Pulmon en Mujeres. A. Sanchez Hernandez: Financial Interests, Personal, Speaker’s Bureau: Roche, AstraZeneca, Takeda, Janssen, Amgen, Pfizer; Financial Interests, Personal, Advisory Board: MSD. C. Aguado de la Rosa: Financial Interests, Personal, Advisory Board: MSD, AstraZeneca, Sanofi, Takeda; Financial Interests, Personal, Invited Speaker: Novartis, Pfizer, Amgen, Regeneron; Financial Interests, Personal, Expert Testimony: Pierre Fabre, BMS; Financial Interests, Personal and Institutional, Invited Speaker: MSD, Mirati, Amgen, AstraZeneca, Lilly; Other, Personal, Other, Support Attending Meetings/Travels: Roche, Pierre Fabre, MSD, Takeda. B. Massuti Sureda: Non-Financial Interests, Personal, Other, Travel Grants: Roche; Financial Interests, Personal, Other, Travel Grants: MSD, AstraZeneca, Bristol Myers Squibb; Financial Interests, Personal, Other: Takeda, BeiGene. M. Baret: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. J.L. Lechuga Martos: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. M. Dominguez: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. L. Paz-Ares: Financial Interests, Personal, Advisory Board, Speaker fees: Roche, MSD, BMS, AstraZeneca, Lilly, PharmaMar, BeiGene, Daiichi Sankyo, Medscape, PER; Financial Interests, Personal, Advisory Board: Merck Serono, Pfizer, Bayer, Amgen, Janssen, GSK, Novartis, Takeda, Sanofi, AbbVie, Gilead, Regeneron; Financial Interests, Personal, Other, Board member: Altum sequencing; Financial Interests, Personal, Other, lectures: AICME; Financial Interests, Personal, Other, Lectures: CCO; Financial Interests, Personal, Expert Testimony: Boehringer Ingelheim; Financial Interests, Personal, Member of Board of Directors, spinn off (I have around 8% of stocks): Altum sequencing; Financial Interests, Personal, Member of Board of Directors: Stab therapeutics; Financial Interests, Personal, Ownership Interest, spin-off (10%): Stab Therapeutics; Financial Interests, Personal, Stocks/Shares, co-founder: Altum sequencing; Financial Interests, Institutional, Invited Speaker: Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme corp, BMS, Janssen-Cilag International NV, Novartis, Roche, Sanofi, Tesaro, Alkermes, Lilly, Takeda, Pfizer, PharmaMar, Cantargia; Financial Interests, Personal, Invited Speaker: Amgen; Financial Interests, Personal, Other, Member: AACR, ASCO, ESMO; Financial Interests, Personal, Other, Foundation Board Member: AECC; Financial Interests, Personal, Other, President. ASEICA(Spanish Association of Cancer Research): ASEICA; Financial Interests, Personal, Other, Foundation president: ONCOSUR; Financial Interests, Personal, Other, member: Small Lung Cancer Group; Non-Financial Interests, Personal, Other, Board member of this anti-cancer Charity: AECC; Non-Financial Interests, Personal, Member, Past-President: ASEICA (Spanish Cancer Research Association); Non-Financial Interests, Personal, Leadership Role, President: Oncosur Foundation. All other authors have declared no conflicts of interest.